Boston, MA – [Insert Date] – The relentless pursuit of effective treatments for Amyotrophic Lateral Sclerosis (ALS) has once again highlighted the formidable challenges faced by pharmaceutical companies. Axoltis Pharma is currently undertaking in-depth analysis of its Phase II SEALS (NCT06365216) trial for its investigational therapy NX210c, following a failure to meet its primary endpoint. While the initial results did not demonstrate a statistically significant benefit in neurofilament light chain (NfL) levels or the albumin quotient between cerebrospinal fluid and blood (Qalb) after six weeks, the company is emphasizing "consistent positive trends" observed in secondary and exploratory measures, signaling a potential path forward in a disease space that has seen a starkly limited number of approved disease-modifying therapies.
The ALS therapeutic landscape remains one of the most arduous in drug development, with only three disease-modifying therapies currently holding U.S. Food and Drug Administration (FDA) approval. This scarcity underscores the immense scientific and clinical hurdles involved in effectively tackling this devastating neurodegenerative disease, which progressively impacts motor neurons, leading to muscle weakness, paralysis, and ultimately, respiratory failure. Against this backdrop, Axoltis Pharma’s commitment to further exploring its data, despite the setback on its primary endpoint, reflects the industry’s persistent dedication to finding viable solutions for ALS patients.
Unpacking the SEALS Trial Results: A Closer Look at NX210c
The SEALS trial, a Phase II study designed to evaluate the safety and efficacy of NX210c in patients with ALS, unfortunately, did not achieve its predefined primary objectives. Specifically, the trial failed to demonstrate a statistically significant difference in the reduction of NfL levels or Qalb between patients treated with NX210c and those receiving a placebo at the six-week mark. NfL, a key biomarker, serves as an indicator of neuronal and axonal damage, and its reduction is often seen as a positive sign in ALS therapeutic development. The Qalb measure, conversely, assesses the integrity of the blood-brain barrier.
Despite the lack of primary endpoint success, Axoltis Pharma has reported a numerical benefit in the decrease of NfL in the blood of patients treated with NX210c. The study indicated that 25.4% of patients in the NX210c arms experienced a reduction in blood NfL, compared to 11.8% in the placebo cohort. While this trend was not statistically significant, it suggests a potential signal that warrants further investigation.
The company’s optimism is primarily fueled by promising results observed in secondary and exploratory endpoints. These "consistent positive trends," as described by Axoltis, offer a more nuanced picture of NX210c’s potential impact.
Post-Hoc Analyses Reveal Encouraging Functional and Biomarker Signals
Axoltis Pharma has delved into post-hoc analyses of the SEALS trial data, uncovering significant findings that could inform the future development of NX210c. These analyses focused on the rate of clinical function decline, as measured by the Harmonised Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) slope.
In a notable finding, the decline rate of clinical function was substantially reduced in patients treated with NX210c compared to the placebo group. The study reported a reduction of 0.67 points per month for the 5mg/kg arm and 0.9 points per month for the 10mg/kg cohort, whereas the placebo group experienced a reduction of 1.14 points per month. This translates to an average reduction of 41% for the 5mg/kg dose and 21% for the 10mg/kg dose over the six-week period. Crucially, this positive effect on functional decline appeared to improve further when assessed at week 10 and continued through four months of observation.
Further dissecting the data, benefits were also observed in the motor function subscale of the ALSFRS-R. At weeks six and 10, patients in the 5mg/kg arm showed an average reduction of approximately 64% in motor function decline, while the 10mg/kg cohort exhibited a 33% reduction. These findings suggest that NX210c may have a positive impact on preserving motor function, a critical aspect of quality of life for individuals living with ALS.
Beyond functional outcomes, Axoltis also highlighted a significant decrease in blood claudin-5 levels in the 10mg/kg cohort. Claudin-5 is a protein released into the bloodstream when the blood-brain barrier (BBB) is disrupted. A reduction in its levels suggests a potential recovery or strengthening of the BBB, a vital protective shield for the brain and spinal cord. Maintaining the integrity of the BBB is increasingly recognized as a crucial factor in managing neurodegenerative diseases.
A Look Ahead: Next Steps for NX210c and the Broader ALS Landscape
Buoyed by the exploratory and secondary endpoint data, Axoltis Pharma is now focused on defining the next clinical steps for NX210c in ALS. The company has initiated additional analyses, including a comprehensive 10-month follow-up of the Phase II trial participants. This extended follow-up is critical for understanding the long-term safety and efficacy profile of NX210c. Furthermore, the company is investigating the pharmacokinetic (PK) and pharmacodynamic (PD) relationships to potentially identify an optimal treatment regimen that maximizes therapeutic benefit while minimizing any potential risks.
Detailed findings from these analyses are slated for presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience, scheduled to take place in Washington D.C. from November 14th to 18th. This prominent scientific forum will provide an opportunity for the broader neuroscience community to engage with Axoltis Pharma’s latest data and insights.
The current situation with Axoltis Pharma’s NX210c trial underscores the inherent difficulties in developing ALS therapies. The field has been marked by a series of setbacks, reinforcing the complexity of the disease and the stringent requirements for regulatory approval.
This past year has seen several high-profile trial disappointments. In August 2026, Novartis quietly reported that its ALS drug candidate, VHB937B1, failed to meet its primary or secondary endpoints in the ASTRALS Phase II trial, leading to the discontinuation of the drug’s development for ALS.
The cautionary tale of Relyvrio (sodium phenylbutyrate and taurursodiol), developed by Amylyx Pharmaceuticals, serves as a stark reminder of the challenges. While granted accelerated approval in 2022, the therapy was ultimately withdrawn from the market in 2024 following the failure of a confirmatory study. This withdrawal highlighted the critical need for robust evidence of clinical benefit to sustain market presence.
Further compounding the difficult landscape, 2024 also witnessed Sanofi and Denali Therapeutics’ ALS therapy, SAR44320, miss its primary endpoint in a Phase II trial. Similarly, Ferrer Internacional’s FAB122 failed to achieve its primary endpoint in a Phase III study during the same year.
Against this backdrop of numerous setbacks, the approvals that have been achieved represent significant milestones. Biogen’s Qalsody (tofersen) received FDA approval in 2023 for a specific subset of patients with SOD1-related genetic ALS. This marked the first approval in the market since Mitsubishi Tanabe Pharma’s Radicava (edaravone) in 2017. Prior to Radicava, the only approved drug for ALS was riluzole, highlighting the long periods between therapeutic advancements.
The Urgent Need for Innovation in ALS Treatment
The consistent failure of investigational therapies to meet primary endpoints in ALS trials, coupled with the limited number of approved treatments, underscores the urgent need for continued innovation and a deeper understanding of the disease’s underlying mechanisms. The challenges are multi-faceted, encompassing the heterogeneity of ALS, the difficulty in identifying reliable and predictive biomarkers, and the complex interplay of genetic and environmental factors that contribute to its progression.
Companies like Axoltis Pharma, despite facing hurdles, are playing a crucial role in advancing the field. Their commitment to thorough data analysis, even in the face of setbacks, and their exploration of secondary and exploratory endpoints demonstrate a dedication to uncovering potential therapeutic avenues. The scientific community will be closely watching the further development of NX210c, as any promising signal, however nascent, offers a glimmer of hope in the challenging fight against ALS. The path forward will undoubtedly require rigorous scientific inquiry, innovative trial designs, and sustained investment to bring meaningful treatments to patients who desperately need them.
About the Author
